A Dozen Years of Discovery: Insights into the Physiology and Pharmacology of FGF21.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30726758.
- Also identified by DOI 10.1016/j.cmet.2019.01.004 and PMC identifier 6368396.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
It has been more than a dozen years since FGF21 burst on the metabolism field in a paper showing that its pharmacologic administration caused weight loss and improved insulin sensitivity and lipoprotein profiles in obese rodents. Since then, FGF21 analogs have advanced all the way to clinical trials, and much progress has been made in understanding FGF21's pharmacology and physiology. In this Perspective, we highlight some of the interesting themes that have emerged from this first dozen years of FGF21 research, including its roles in autocrine/paracrine and endocrine responses to metabolic stress.
Medical subject headings
- Fibroblast Growth Factors
- Obesity
- Weight Loss